Clinical trial · no report yet · Phase 3
IDeate-Lung02
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- NCT06203210 ↗
- Recruiting
- Daiichi Sankyo
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 18 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan; Topotecan; Amrubicin; Lurbinectedin
- Arms
- Ifinatamab deruxtecan (I-DXd) · Experimental
- Treatment of Physician's Choice (TPC) · Active comparator
- Enrollment
- 540 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Daiichi Sankyo with Merck Sharp & Dohme LLC
- Start
- May 21, 2024
- Primary completion
- Jan 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06203210 · updated Aug 6, 2026
Publications
linked from the registry- Owonikoko TK, Byers L, Cheng Y, Hayashi H, Paz-Ares L, Perol M, Hu H, Qian M, Garcia CR, Godard J, Tang M, Rudin CM. IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. Future Oncol. 2025 Oct;21(25):3275-3282. doi: 10.1080/14796694.2025.2565995. Epub 2025 Oct 7. PubMed 41055143